Archives to Collect Info on Radiation Exposure Worldwide

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 2
Volume 7
Issue 2

SPOKANE, Wash-A new organization is collecting health histories from people exposed to radiation from nuclear weapons production worldwide, to provide an international source of in-formation.

SPOKANE, Wash—A new organization is collecting health histories from people exposed to radiation from nuclear weapons production worldwide, to provide an international source of in-formation.

The Radiation Health Effects Archives, located on the campus of Gonzaga University, will continue and expand the collection of the Hanford Health Information Archives, founded last year to collect information about the experiences of people who lived in the region around the Hanford, Washington, nuclear facility between 1944 and 1972. These individuals are sometimes referred to as “Hanford downwinders.”

The Hanford-exposure area includes Eastern Washington, northeastern Oregon, and much of Idaho, plus areas along the Columbia River downstream from Hanford. The facility’s airborne emissions were also carried by the wind into parts of Montana and Canada.

The Archives have processed more than 400 donations with information from more than 1,100 downwinders. People have donated medical records, oral histories, journals, yearbooks, photographs, and other items that help describe their lifestyles and diets, as well as their health, from the mid-1940s to the present.

The data are available online at http://www.foley.gonzaga.edu/hhiahome.html. Comments and questions can be sent via e-mail to hhia@foley.gonzaga.edu.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content